HOUSTON — Bristol Myers Squibb (NYSE: BMY), a global pharmaceutical company best known for manufacturing treatments and medications such as Opdivo and Eliquis, will open a $2.3 billion manufacturing campus in Houston. The Princeton, N.J.-based firm chose a site within McCord Development’s 4,300-acre Generation Park for the approximately 600,000-square-foot project. “This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” says Christopher Boerner, board chair and CEO of Bristol Myers Squibb. “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure and partnership needed to help bring that vision to life.” Situated in northeast Houston, Bristol Myers Squibb’s new campus will be designed to be both modular and multi-modal, allowing the company to reconfigure manufacturing capacity for multiple types of medicines — including small molecules, biologics and antibody-drug conjugates — as needs arise. The new campus is estimated to create nearly 500 skilled jobs in the Houston area for roles including operations technicians, production specialists, maintenance and engineering professionals, quality control/assurance experts and administration. Bristol Myers Squibb also anticipates …
